Prodotti competitors / Area Kite
Brentuximab vedotin - EU Orphan designation for Hodgkin's lymphoma, Peripheral T-cell lymphoma and Cutaneous T-cell lymphoma
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
Brentuximab vedotin on 26 June 2024 received the orphan designation in the EU for the following treatment:
Grazie per il tuo feedback!